Heart Failure, ICD, Lead, Ventricular Arrythmia
Conditions
Keywords
INVICTA, Lead, ICD, CRT-D, MicroPort
Brief summary
The primary objective of this study is to assess the safety and key electrical performance of the INVICTA leads equipped with DF4 connector: ACTIVE fixation type models (single and dual coil: INVICTA 1CR, INVICTA 2CR) and PASSIVE fixation type models (single and dual coil: INVICTA 1CT, INVICTA 2CT).
Detailed description
FRIENDS study is a pre-market approval (INVICTA leads - devices under investigation - are not CE marked), interventional, prospective, longitudinal, international (European), multicenter, single arm study. The devices under investigation, the INVICTA defibrillation leads, are new quadripolar leads, to be used with Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators (ICD/CRT-D). This clinical study intends to demonstrate safety and electrical performances of the INVICTA leads among the different models: active fixation either single coil (model 1CR) or dual coil (model 2CR) and passive fixation, either single coil (model 1CT) or dual coil (model 2CT) leads models. The clinical data will be used to support the application to CE marking of INVICTA leads. The primary endpoints will be evaluated at 3 months post-implantation; secondary endpoints will be evaluated up to 2 years post-implantation. A maximum number of 224 patients will be enrolled in the study, in up to 60 centers in Europe. The follow-up visits are scheduled at hospital discharge, at 1 month, at 3 months, at 6 months, at 12 months, at 18 months and at 24 months, post-implant .
Interventions
DEVICEImplant of the INVICTA lead
The implant or the attempt to implant an INVICTA lead
Sponsors
MicroPort CRM
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Any patient presenting an ICD or CRT-D indication as detailed in the latest European Society of Cardiology (ESC) guidelines 2. Scheduled for a primary implant of an ICD / CRT-D, manufactured by MicroPort CRM and equipped with a RV DF4 connector 3. Signed and dated informed consent
Exclusion criteria
1. Tricuspid valvular disease or tricuspid replacement heart valve (mechanical or tissue) 2. Transient tachyarrhythmias due to reversible causes (such as drug intoxication, electrolyte imbalance, sepsis, hypoxia or other factors as myocardial infarction or electric shock) 3. Contraindication to a maximum single dose of 330 µg dexamethasone sodium phosphate (DSP) 4. Active myocarditis 5. Already included in another clinical study that could confound the results of this study 6. Inability to understand the purpose of the study or to meet follow-up visits at the implanting centre as defined in the investigational plan 7. Patient less than 18 years old or under guardianship or kept in detention 8. Known pregnancy, women in breastfeeding or in childbearing age without an adequate contraceptive method 9. Drug addiction or abuse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from INVICTA lead-related complications | 90 days | Freedom from INVICTA lead-related complications as assessed by an independent events adjudicator and defined as any INVICTA lead-related serious adverse device effect (SADE) that resulted in patient death or required an additional invasive intervention. |
| INVICTA lead electrical performance at 3 months | 3 months | Right Ventricular (RV) pacing threshold (V) of the INVICTA lead, measured by the implanted ICD/CRT-D with 0.5 ms pulse width |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| INVICTA sensing threshold | 24 months | RV lead endocardial R wave amplitude (mV), measured by the implanted ICD/CRT-D |
| Percentage of the shocks that successfully terminate a ventricular arrhythmia episode | 24 months | Percentage of endocardial shock therapies that successfully terminate ventricular arrhythmia episodes, calculated as the proportion of successful shocks on the total number of shocks delivered during defibrillation testing or spontaneous ventricular arrhythmias. |
| INVICTA lead complication free-rate up to 24 months | 24 months | Report of INVICTA lead complication free-rate (complication defined as any INVICTA lead-related serious adverse device effect (SADE) that resulted in patient death or required an additional invasive intervention) up to 24 months post-implantation |
| INVICTA lead pacing threshold | 24 months | RV lead pacing threshold amplitude (V), measured by the implanted ICD/CRT-D with 0.5 ms pulse width |
| INVICTA lead handling assessment | At Implant (Day 0) | Summary of the investigators' opinion about INVICTA handling at implant |
| INVICTA lead implant success rate | At Implant (Day 0) | % of enrolled patients successfully implanted with an INVICTA lead |
| INVICTA lead-related Serious Adverse Events and device deficiencies up to 24 months | 24 months | Report of INVICTA lead-related SADEs and device deficiencies occurred up to 24 months post-implantation |
| INVICTA lead impedances | 24 months | RV lead pacing impedance (Ohm) and defibrillation coil impedance (Ohm), measured by the implanted ICD/CRT-D |
Countries
France, Italy, Portugal, Spain
Outcome results
None listed